Missing Huntington's Disease for Tardive Dyskinesia: A Preventable Error

被引：5
|
作者：
Kumar, Hrishikesh [1 ]
Jog, Mandar [1 ]
机构：
[1] Univ Western Ontario, London Hlth Sci Ctr, Movement Disorders Program, London, ON N6A 5A5, Canada
来源：
CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES | 2011年 / 38卷 / 05期
关键词：
D O I：
10.1017/S0317167100012294
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
[No abstract available]
引用
收藏
页码：762 / 764
页数：3
相关论文
共 50 条
  • [1] Rapid onset of tardive dyskinesia in Huntington disease with olanzapine
    Benazzi, F
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2002, 22 (04) : 438 - 439
  • [2] Deutetrabenazine (Austedo) for Huntington's Chorea and Tardive Dyskinesia
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2018, 60 (1545): : 65 - 68
  • [3] VOLUNTARY MOVEMENT DYSFUNCTION IN HUNTINGTON DISEASE AND TARDIVE-DYSKINESIA
    DAVID, AS
    JESTE, DV
    FOLSTEIN, MF
    FOLSTEIN, SE
    ACTA NEUROLOGICA SCANDINAVICA, 1987, 75 (02): : 130 - 139
  • [4] Deutetrabenazine: Treatment of hyperkinetic aspects of Huntington's disease, tardive dyskinesia and Tourette syndrome
    Paton, D. M.
    DRUGS OF TODAY, 2017, 53 (02) : 89 - 102
  • [5] NMDA receptor co-determines vulnerability to develop dyskinesia in Huntington's Disease and levodopa-induced dyskinesia but not tardive dyskinesia
    Loonen, A. J. M.
    Ivanova, S. A.
    Pechlivanoglou, P.
    Rudikov, E.
    Zhukova, I.
    Al Hadithy, A. F. Y.
    Alifirova, V.
    Brouwers, J. R. B. J.
    Semke, A.
    Wilffert, B.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2011, 21 : S142 - S142
  • [6] Real-World Deutetrabenazine Dosing Patterns in Patients With Huntington's Disease or Tardive Dyskinesia
    Ayyagari, R.
    Wilhelm, A.
    Alexander, J.
    Chaijale, N.
    Garcia-Horton, V.
    Devine, F.
    Carroll, B.
    MOVEMENT DISORDERS, 2020, 35 : S31 - S31
  • [7] Safety of Deutetrabenazine for the Treatment of Tardive Dyskinesia and Chorea Associated with Huntington Disease
    Frank, Samuel
    Anderson, Karen E.
    Fernandez, Hubert H.
    Hauser, Robert A.
    Claassen, Daniel O.
    Stamler, David
    Factor, Stewart A.
    Jimenez-Shahed, Joohi
    Barkay, Hadas
    Wilhelm, Amanda
    Alexander, Jessica K.
    Chaijale, Nayla
    Barash, Steve
    Savola, Juha-Matti
    Gordon, Mark Forrest
    Chen, Maria
    NEUROLOGY AND THERAPY, 2024, 13 (03) : 655 - 675
  • [8] Predictors of persistence to deutetrabenazine among patients with tardive dyskinesia (TD) and Huntington's disease (HD)
    Claassen, D.
    Ayyagari, R.
    Garcia-Horton, V.
    Zhang, S.
    Leo, S.
    MOVEMENT DISORDERS, 2021, 36 : S30 - S31
  • [9] Deutetrabenazine for tardive dyskinesia and chorea associated with Huntington?s disease: a review of clinical trial data
    Claassen, Daniel O.
    Philbin, Michael
    Carroll, Benjamin
    EXPERT OPINION ON PHARMACOTHERAPY, 2019, 20 (18) : 2209 - 2221
  • [10] Clinical Utility of Deutetrabenazine as a Treatment Option for Chorea Associated with Huntington's Disease and Tardive Dyskinesia
    Frank, Samuel
    Alakkas, Aljoharah
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2023, 19 : 1019 - 1024
12345